Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine

Margherita Fabbri, Joaquim J. Ferreira, Andrew Lees, Fabrizio Stocchi, Werner Poewe, Eduardo Tolosa, Olivier Rascol

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Catechol-O-methyl transferase inhibitors are currently used as first-line add-on therapy to levodopa for the treatment of end-of-dose motor fluctuations in Parkinson's disease patients, as they increase levodopa bioavailability. Several factors hamper the use of current available catechol-O-methyl transferase inhibitors, that is, the moderate efficacy and multiple dosing for entacapone and the risk of liver toxicity with tolcapone. Opicapone, a new long-acting, peripherally selective, once-daily catechol-O-methyl transferase inhibitor, was recently licensed in Europe. Two phase 3 double-blind clinical trials demonstrated opicapone efficacy in reducing OFF time by an average of about 60 minutes daily compared with placebo, without increasing ON time with troublesome dyskinesias. These effects were also maintained during a subsequent open-label extension consisting of 1-year follow-up. Opicapone showed a good safety profile. From June 2016, Opicapone received the approval for marketing authorization from the European Commission as adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in patients with PD and end-of-dose motor fluctuations. We aimed to review the clinical pharmacological data of opicapone, summarize its clinical efficacy and safety issues, and discuss its potential role in the management of Parkinson's disease.

Original languageEnglish
Pages (from-to)1528-1539
Number of pages12
JournalMovement Disorders
Volume33
Issue number10
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Parkinson Disease
Guaiacol
Medicine
Levodopa
Transferases
Therapeutics
Safety
Dyskinesias
Marketing
Biological Availability
Placebos
opicapone
Clinical Trials
Pharmacology
Liver

Keywords

  • advanced stage
  • COMT inhibitor
  • motor fluctuations
  • opicapone
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Fabbri, M., Ferreira, J. J., Lees, A., Stocchi, F., Poewe, W., Tolosa, E., & Rascol, O. (2018). Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. Movement Disorders, 33(10), 1528-1539. https://doi.org/10.1002/mds.27475

Opicapone for the treatment of Parkinson's disease : A review of a new licensed medicine. / Fabbri, Margherita; Ferreira, Joaquim J.; Lees, Andrew; Stocchi, Fabrizio; Poewe, Werner; Tolosa, Eduardo; Rascol, Olivier.

In: Movement Disorders, Vol. 33, No. 10, 01.10.2018, p. 1528-1539.

Research output: Contribution to journalReview article

Fabbri, M, Ferreira, JJ, Lees, A, Stocchi, F, Poewe, W, Tolosa, E & Rascol, O 2018, 'Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine', Movement Disorders, vol. 33, no. 10, pp. 1528-1539. https://doi.org/10.1002/mds.27475
Fabbri, Margherita ; Ferreira, Joaquim J. ; Lees, Andrew ; Stocchi, Fabrizio ; Poewe, Werner ; Tolosa, Eduardo ; Rascol, Olivier. / Opicapone for the treatment of Parkinson's disease : A review of a new licensed medicine. In: Movement Disorders. 2018 ; Vol. 33, No. 10. pp. 1528-1539.
@article{06b15b5019ea4f978ddddecb4e2e6fcf,
title = "Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine",
abstract = "Catechol-O-methyl transferase inhibitors are currently used as first-line add-on therapy to levodopa for the treatment of end-of-dose motor fluctuations in Parkinson's disease patients, as they increase levodopa bioavailability. Several factors hamper the use of current available catechol-O-methyl transferase inhibitors, that is, the moderate efficacy and multiple dosing for entacapone and the risk of liver toxicity with tolcapone. Opicapone, a new long-acting, peripherally selective, once-daily catechol-O-methyl transferase inhibitor, was recently licensed in Europe. Two phase 3 double-blind clinical trials demonstrated opicapone efficacy in reducing OFF time by an average of about 60 minutes daily compared with placebo, without increasing ON time with troublesome dyskinesias. These effects were also maintained during a subsequent open-label extension consisting of 1-year follow-up. Opicapone showed a good safety profile. From June 2016, Opicapone received the approval for marketing authorization from the European Commission as adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in patients with PD and end-of-dose motor fluctuations. We aimed to review the clinical pharmacological data of opicapone, summarize its clinical efficacy and safety issues, and discuss its potential role in the management of Parkinson's disease.",
keywords = "advanced stage, COMT inhibitor, motor fluctuations, opicapone, Parkinson's disease",
author = "Margherita Fabbri and Ferreira, {Joaquim J.} and Andrew Lees and Fabrizio Stocchi and Werner Poewe and Eduardo Tolosa and Olivier Rascol",
year = "2018",
month = "10",
day = "1",
doi = "10.1002/mds.27475",
language = "English",
volume = "33",
pages = "1528--1539",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Opicapone for the treatment of Parkinson's disease

T2 - A review of a new licensed medicine

AU - Fabbri, Margherita

AU - Ferreira, Joaquim J.

AU - Lees, Andrew

AU - Stocchi, Fabrizio

AU - Poewe, Werner

AU - Tolosa, Eduardo

AU - Rascol, Olivier

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Catechol-O-methyl transferase inhibitors are currently used as first-line add-on therapy to levodopa for the treatment of end-of-dose motor fluctuations in Parkinson's disease patients, as they increase levodopa bioavailability. Several factors hamper the use of current available catechol-O-methyl transferase inhibitors, that is, the moderate efficacy and multiple dosing for entacapone and the risk of liver toxicity with tolcapone. Opicapone, a new long-acting, peripherally selective, once-daily catechol-O-methyl transferase inhibitor, was recently licensed in Europe. Two phase 3 double-blind clinical trials demonstrated opicapone efficacy in reducing OFF time by an average of about 60 minutes daily compared with placebo, without increasing ON time with troublesome dyskinesias. These effects were also maintained during a subsequent open-label extension consisting of 1-year follow-up. Opicapone showed a good safety profile. From June 2016, Opicapone received the approval for marketing authorization from the European Commission as adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in patients with PD and end-of-dose motor fluctuations. We aimed to review the clinical pharmacological data of opicapone, summarize its clinical efficacy and safety issues, and discuss its potential role in the management of Parkinson's disease.

AB - Catechol-O-methyl transferase inhibitors are currently used as first-line add-on therapy to levodopa for the treatment of end-of-dose motor fluctuations in Parkinson's disease patients, as they increase levodopa bioavailability. Several factors hamper the use of current available catechol-O-methyl transferase inhibitors, that is, the moderate efficacy and multiple dosing for entacapone and the risk of liver toxicity with tolcapone. Opicapone, a new long-acting, peripherally selective, once-daily catechol-O-methyl transferase inhibitor, was recently licensed in Europe. Two phase 3 double-blind clinical trials demonstrated opicapone efficacy in reducing OFF time by an average of about 60 minutes daily compared with placebo, without increasing ON time with troublesome dyskinesias. These effects were also maintained during a subsequent open-label extension consisting of 1-year follow-up. Opicapone showed a good safety profile. From June 2016, Opicapone received the approval for marketing authorization from the European Commission as adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in patients with PD and end-of-dose motor fluctuations. We aimed to review the clinical pharmacological data of opicapone, summarize its clinical efficacy and safety issues, and discuss its potential role in the management of Parkinson's disease.

KW - advanced stage

KW - COMT inhibitor

KW - motor fluctuations

KW - opicapone

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=85053872326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053872326&partnerID=8YFLogxK

U2 - 10.1002/mds.27475

DO - 10.1002/mds.27475

M3 - Review article

C2 - 30264443

AN - SCOPUS:85053872326

VL - 33

SP - 1528

EP - 1539

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 10

ER -